Solstice Oncology develops immuno-oncology therapies focused on treating and preventing cancer through targeted approaches.
Solstice Oncology has raised $225.0M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Solstice Oncology's investors include RA Capital Management, Forbion Capital Partners, Canaan Partners.
Solstice Oncology is headquartered in Boston, United States.
Solstice Oncology develops immuno-oncology therapies focused on treating and preventing cancer through targeted approaches.
Solstice Oncology is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Solstice Oncology — Funding & Investors." VCBacked, September 9, 2026, https://www.vcbacked.co/company/solstice-oncology. Accessed September 30, 2026.
VCBacked. (2026). Solstice Oncology — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/solstice-oncology
{{cite web |title=Solstice Oncology — Funding & Investors |url=https://www.vcbacked.co/company/solstice-oncology |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated